SCHEMBL30765780

SCHEMBL30765780

O=C(Cn1c(N2CCOCC2)ncc(NC(=O)c2cnc(-c3ccccc3)o2)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 5/20 0.40
AKT1 P31749 2/20 0.37
SRPK1 Q96SB4 1/20 0.37
TRPV1 Q8NER1 2/20 0.36
DGAT1 O75907 2/20 0.35
NTRK1 P04629 1/20 0.35
HDAC1 Q13547 1/20 0.35
F3 P13726 2/20 0.34
MAPT P10636 1/20 0.34
GSK3A P49840 1/20 0.34
F2 P00734 2/20 0.34
CCNK O75909 1/20 0.34
CDK12 Q9NYV4 1/20 0.34
CYP2C9 P11712 1/20 0.34
F7 P08709 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765915 0.84 SMN1; SMN2 (0.39) NAMPTAKT1TRPV1F2CCNK
SCHEMBL30765852 0.83 NTRK1 (0.38) NAMPTSRPK1TRPV1DGAT1NTRK1
SCHEMBL30765657 0.82 F2 (0.36) NAMPTAKT1TRPV1NTRK1F3
SCHEMBL30765553 0.81 MAPK1 (0.37) NAMPTAKT1NTRK1F3F2
SCHEMBL31751198 0.79 MAPK1 (0.36) NAMPTNTRK1F2CCNKCDK12
SCHEMBL30766050 0.77 ELANE (0.41) SRPK1NTRK1F3F2
SCHEMBL30765627 0.77 DGAT2 (0.39) NTRK1HDAC1F3F2MAPK1
SCHEMBL30765851 0.76 NTRK1 (0.40) NAMPTNTRK1HDAC1F3
SCHEMBL30765732 0.76 NTRK1 (0.40) SRPK1DGAT1NTRK1HDAC1F3
SCHEMBL30765840 0.76 NAMPT (0.38) NAMPTAKT1DGAT1NTRK1F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed